A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...

The US FDA has accepted the supplemental biologics license application (sBLA) for trastuzumab deruxtecan (T-DXd; Enhertu) ...

In the phase 1 clinical trial (NCT03155061) 3 in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, the combination of ONO-4578 and nivolumab ...

Received folinic acid/fluorouracil/oxaliplatin/bevacizumab in first line with initial partial response; progression after 11 ...

Prepare for a pivotal shift in the molecular oncology landscape at the 2025 European Society of Medical Oncology (ESMO) Annual Congress, to be held October 17 through 21, in Berlin, Germany.

Innovative research transforms bone marrow transplantation, enhancing outcomes with mismatched and haploidentical donors, expanding access to life-saving treatments.

The fast track designation is supported by preclinical evidence of antitumor activity by ADCE-D01 in several STS tumor models ...

Despite the necessity of relying on these alternative, historically less-preferred donor types, the study's central finding held true: the transplant outcomes (survival, engraftment, and complication ...

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...